Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Improving combination cancer therapy: the CombiPlex® development platform.

Tolcher AW, Mayer LD.

Future Oncol. 2018 Jun;14(13):1317-1332. doi: 10.2217/fon-2017-0607. Epub 2018 Jan 24.

2.

Caged Naloxone: Synthesis, Characterization, and Stability of 3- O-(4,5-Dimethoxy-2-nitrophenyl)carboxymethyl Naloxone (CNV-NLX).

Lewin AH, Fix SE, Zhong D, Mayer LD, Burgess JP, Mascarella SW, Reddy PA, Seltzman HH, Carroll FI.

ACS Chem Neurosci. 2018 Mar 21;9(3):563-567. doi: 10.1021/acschemneuro.7b00378. Epub 2017 Dec 8.

PMID:
29154536
3.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

Gordon MJ, Tardi P, Loriaux MM, Spurgeon SE, Traer E, Kovacsovics T, Mayer LD, Tyner JW.

Leuk Res. 2017 Feb;53:39-49. doi: 10.1016/j.leukres.2016.12.002. Epub 2016 Dec 12.

PMID:
28013106
4.

Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.

Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, Smith MA, Lock RB.

Pediatr Blood Cancer. 2015 Jan;62(1):65-71. doi: 10.1002/pbc.25133. Epub 2014 Sep 9.

5.

Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.

Liboiron BD, Mayer LD.

Ther Deliv. 2014 Feb;5(2):149-71. doi: 10.4155/tde.13.149. Review.

PMID:
24483194
6.

Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.

Stern ST, Zou P, Skoczen S, Xie S, Liboiron B, Harasym T, Tardi P, Mayer LD, McNeil SE.

J Control Release. 2013 Dec 10;172(2):558-67. doi: 10.1016/j.jconrel.2013.04.025. Epub 2013 May 9.

7.

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.

Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, Mayer LD, Louie AC, Lancet JE.

Leuk Res. 2012 Oct;36(10):1283-9. doi: 10.1016/j.leukres.2012.07.006. Epub 2012 Jul 26.

PMID:
22840315
8.

Effects of block copolymer properties on nanocarrier protection from in vivo clearance.

D'Addio SM, Saad W, Ansell SM, Squiers JJ, Adamson DH, Herrera-Alonso M, Wohl AR, Hoye TR, Macosko CW, Mayer LD, Vauthier C, Prud'homme RK.

J Control Release. 2012 Aug 20;162(1):208-17. doi: 10.1016/j.jconrel.2012.06.020. Epub 2012 Jun 23.

9.

Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.

Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE.

Exp Hematol. 2011 Jul;39(7):741-50. doi: 10.1016/j.exphem.2011.04.001. Epub 2011 Apr 9.

PMID:
21530609
10.

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC.

J Clin Oncol. 2011 Mar 10;29(8):979-85. doi: 10.1200/JCO.2010.30.5961. Epub 2011 Jan 31.

11.

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG.

Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Review.

PMID:
21118030
12.

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.

Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD.

Leuk Lymphoma. 2010 Aug;51(8):1536-42. doi: 10.3109/10428194.2010.490312.

PMID:
20528246
13.

Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.

Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD.

Int J Pharm. 2010 May 31;391(1-2):248-59. doi: 10.1016/j.ijpharm.2010.02.014. Epub 2010 Feb 13.

PMID:
20156541
14.

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, Huang X, Harasym TO, Bermudes D, Mayer LD.

Leuk Res. 2010 Sep;34(9):1214-23. doi: 10.1016/j.leukres.2010.01.015. Epub 2010 Feb 6.

PMID:
20138667
15.

Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.

Harasym TO, Liboiron BD, Mayer LD.

Methods Mol Biol. 2010;596:291-323. doi: 10.1007/978-1-60761-416-6_13. Review.

PMID:
19949929
16.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD.

Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11.

17.

Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.

Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC.

Clin Cancer Res. 2009 Jan 15;15(2):692-700. doi: 10.1158/1078-0432.CCR-08-0515.

18.

Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse.

Bayne WF, Mayer LD, Swenson CE.

J Pharm Sci. 2009 Jul;98(7):2540-8. doi: 10.1002/jps.21620.

PMID:
19009594
19.

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.

Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud'homme RK, Mayer LD.

J Med Chem. 2008 Jun 12;51(11):3288-96. doi: 10.1021/jm800002y. Epub 2008 May 9.

PMID:
18465845
20.

Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

Dicko A, Frazier AA, Liboiron BD, Hinderliter A, Ellena JF, Xie X, Cho C, Weber T, Tardi PG, Cabral-Lilly D, Cafiso DS, Mayer LD.

Pharm Res. 2008 Jul;25(7):1702-13. doi: 10.1007/s11095-008-9561-z. Epub 2008 Mar 5.

PMID:
18320294
21.
22.

Optimizing combination chemotherapy by controlling drug ratios.

Mayer LD, Janoff AS.

Mol Interv. 2007 Aug;7(4):216-23. Review.

PMID:
17827442
23.

The mentored clinical casebook project at Harvard Medical School.

Stanton RC, Mayer LD, Oriol NE, Treadway KK, Tosteson DC.

Acad Med. 2007 May;82(5):516-20.

PMID:
17457078
24.

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.

Biochim Biophys Acta. 2007 Mar;1768(3):678-87. Epub 2006 Dec 6.

25.

In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.

Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB.

Eur J Pharm Biopharm. 2007 Mar;65(3):289-99. Epub 2006 Oct 17.

PMID:
17123800
26.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

27.

Effects of phospholipid hydrolysis on the aggregate structure in DPPC/DSPE-PEG2000 liposome preparations after gel to liquid crystalline phase transition.

Ickenstein LM, Sandström MC, Mayer LD, Edwards K.

Biochim Biophys Acta. 2006 Feb;1758(2):171-80. Epub 2006 Mar 10.

28.

Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes.

Sandström MC, Ickenstein LM, Mayer LD, Edwards K.

J Control Release. 2005 Sep 20;107(1):131-42.

PMID:
16023753
29.

pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.

Guns ES, Xie X, Fedoruk M, Madera C, Cowell S, Mayer LD, Skov K, Gleave ME, Kozlowski P.

Prostate. 2005 Aug 1;64(3):316-22.

PMID:
15754319
30.

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.

Methods Enzymol. 2005;391:71-97.

PMID:
15721375
31.

Preparation, characterization, and biological analysis of liposomal formulations of vincristine.

Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS.

Methods Enzymol. 2005;391:40-57.

PMID:
15721373
32.
33.

Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.

Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB.

Clin Cancer Res. 2004 Oct 1;10(19):6638-49.

34.

An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.

Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB.

J Control Release. 2004 May 18;96(3):449-61.

PMID:
15120901
35.

P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.

Fedoruk MN, Giménez-Bonafé P, Guns ES, Mayer LD, Nelson CC.

Prostate. 2004 Apr 1;59(1):77-90.

PMID:
14991868
36.

pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol.

Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB.

Biochim Biophys Acta. 2004 Feb 10;1661(1):47-60.

37.

Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.

Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M.

Clin Cancer Res. 2004 Feb 1;10(3):1160-9.

38.
39.

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB.

Cancer Biol Ther. 2004 Feb;3(2):197-204. Epub 2004 Feb 1.

PMID:
14726684
40.

High ceramide content liposomes with in vivo antitumor activity.

Shabbits JA, Mayer LD.

Anticancer Res. 2003 Sep-Oct;23(5A):3663-9.

PMID:
14666662
41.

Tumor chemosensitization strategies based on apoptosis manipulations.

Shabbits JA, Hu Y, Mayer LD.

Mol Cancer Ther. 2003 Aug;2(8):805-13. Review. No abstract available.

42.

Disc formation in cholesterol-free liposomes during phase transition.

Ickenstein LM, Arfvidsson MC, Needham D, Mayer LD, Edwards K.

Biochim Biophys Acta. 2003 Aug 7;1614(2):135-8.

43.

Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.

Clin Cancer Res. 2003 Jul;9(7):2826-36.

44.
46.

Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.

Shabbits JA, Mayer LD.

Biochim Biophys Acta. 2003 May 2;1612(1):98-106.

47.
49.
50.

Supplemental Content

Loading ...
Support Center